| abstract |
Cancer vaccines are prepared by treat-ing tumor cells or fibroblasts with a complex of immunostimulating polypeptide-coding DNA and of DNA-binding substance, for example polylysine, preferably conjugated with transferrine. The complex further contains a conjugate of DNA-binding substance and of an endosomolytic peptide or an adenoviras having at least one E4 defect or one E1a defect associated with other genetic defects. |